EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Quantitative and Clinical Pharmacology Perspectives on Next‐Generation Malaria Prevention Using Vaccines and Long‐Acting Monoclonal Antibodies

Sabiha R Mim iD, Leonardo C Xavier iD, Francine J Azeredo iD, Sihem Ait-Oudhia iD

Clinical and Translational Science · 2026-08 · 19 (8)

DOI: 10.1111/cts.70704 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, online erschienen am 12.08.2026. Verfasst von Sabiha R Mim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, Florida, USA. Hauptthemen laut MEDLINE: Malaria Vaccines, Antibodies, Monoclonal, Malaria, Malaria, Falciparum. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malaria remains a significant global health burden, particularly among pediatric populations in endemic regions. Recent advances in preventive interventions highlight the complementary roles of vaccines and long‐acting monoclonal antibodies (mAbs) in reducing infection risk. Vaccines such as RTS,S/AS01 and R21/Matrix‐M induce active immunity through polyclonal antibody and CD4 + T‐cell responses against the circumsporozoite protein (CSP), providing durable, population‐level protection. In contrast, mAbs including CIS43LS and L9LS confer immediate, passive immunity, with protection directly linked to systemic exposure and duration above protective thresholds. Translational pharmacokinetic/pharmacodynamic (PK/PD) modeling and physiologically based pharmacokinetic (PBPK) approaches are central to optimizing these interventions. Population PK models, combined with controlled human malaria infection (CHMI) studies, enable model‐informed selection of dose, route, and timing to achieve efficacious exposures, while PBPK models facilitate extrapolation to pediatric and special populations by incorporating developmental physiology, protein turnover, and FcRn‐mediated recycling. Clinical studies demonstrate robust protection from both vaccines and mAbs, supporting complementary combination strategies. Forward‐looking approaches integrate vaccines and long‐acting mAbs to leverage broad, durable immunity from vaccines and immediate, predictable protection from antibodies, particularly during seasonal peaks or in high‐risk groups. This review emphasizes how quantitative PK/PD and PBPK modeling provide a framework to optimize dosing, predict durability of protection, and guide clinical development across diverse populations. These strategies underscore the value of model‐informed translational pharmacology in accelerating development of next‐generation malaria preventive interventions against malaria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Malaria VaccinesAntibodies, MonoclonalMalariaMalaria, FalciparumHumansPlasmodium falciparumAnimalsHuman Challenge Trials as TopicAntimalarialsProtozoan Proteins

Stichwörter der Autor:innen

controlled human malaria infection (CHMI)long‐acting monoclonal antibodiesmalaria preventionmodel‐informed drug developmentvaccines

Substanzen

Malaria VaccinesAntibodies, MonoclonalAntimalarialsProtozoan Proteins

Autor:innen und Institutionen

  • Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, Florida, USA.
  • Quantitative Pharmacology and Pharmacometrics (QP2), Merck & Co., Inc, Rahway, New Jersey, USA.

ORCID-Profile: Sabiha R Mim, Leonardo C Xavier, Francine J Azeredo, Sihem Ait-Oudhia

Zitieren

APA

Mim, S. R., Xavier, L. C., Azeredo, F. J., & Ait-Oudhia, S. (2026). Quantitative and Clinical Pharmacology Perspectives on Next‐Generation Malaria Prevention Using Vaccines and Long‐Acting Monoclonal Antibodies. Clinical and Translational Science, 19(8). https://doi.org/10.1111/cts.70704

Vancouver

Mim SR, Xavier LC, Azeredo FJ, Ait-Oudhia S. Quantitative and Clinical Pharmacology Perspectives on Next‐Generation Malaria Prevention Using Vaccines and Long‐Acting Monoclonal Antibodies. Clinical and Translational Science. 2026;19(8). doi:10.1111/cts.70704

BibTeX
@article{Mim2026,
  author = {Mim, Sabiha R and Xavier, Leonardo C and Azeredo, Francine J and Ait-Oudhia, Sihem},
  title = {Quantitative and Clinical Pharmacology Perspectives on Next‐Generation Malaria Prevention Using Vaccines and Long‐Acting Monoclonal Antibodies},
  journal = {Clinical and Translational Science},
  year = {2026},
  volume = {19},
  number = {8},
  doi = {10.1111/cts.70704}
}
Kostenlos starten →